TI
CLDX icon

Trexquant Investment’s Celldex Therapeutics CLDX Stock Holding History

Trexquant Investment’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.87M Buy
+184,524
New +$5.96M 0.04% 587
2025
Q3 		– Sell
-112,464
Closed -$2.29M – 1628
2025
Q2 		$2.29M Buy
112,464
+34,254
+44% +$667K 0.03% 841
2025
Q1 		$1.42M Buy
+78,210
New +$1.75M 0.02% 977
2024
Q3 		– Sell
-12,092
Closed -$448K – 1561
2024
Q2 		$448K Sell
12,092
-75,930
-86% -$2.86M 0.01% 1279
2024
Q1 		$3.69M Buy
88,022
+56,593
+180% +$2.32M 0.07% 417
2023
Q4 		$1.25M Buy
+31,429
New +$924K 0.03% 743
2022
Q4 		– Sell
-13,316
Closed -$374K – 1405
2022
Q3 		$374K Buy
+13,316
New +$408K 0.01% 932
2022
Q1 		– Sell
-8,889
Closed -$343K – 1397
2021
Q4 		$343K Buy
8,889
+1,680
+23% +$73.2K 0.02% 846
2021
Q3 		$389K Buy
+7,209
New +$338K 0.03% 635
2015
Q4 		– Sell
-14,006
Closed -$2.21M – 1042
2015
Q3 		$2.21M Buy
14,006
+11,746
+520% +$3.32M 0.19% 129
2015
Q2 		$854K Sell
2,260
-3,513
-61% -$1.4M 0.1% 391
2015
Q1 		$2.41M Buy
5,773
+1,629
+39% +$583K 0.25% 60
2014
Q4 		$1.13M Buy
+4,144
New +$1.03M 0.2% 114

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Trexquant Investment's CLDX Position: Q2 2026 in Review

Trexquant Investment opened a new position in Celldex Therapeutics (CLDX) in Q2 2026: 184,524 shares worth $6.87M. The stake represents 0.04% of the portfolio and ranks #587 among its holdings. This is a return to the name: Trexquant Investment previously reported a position in CLDX as recently as Q2 2025.

Trexquant Investment first reported a position in CLDX in Q4 2014 and has held it in 13 quarters since. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Trexquant Investment held 184,524 shares of Celldex Therapeutics worth $6.87M as of Q2 2026.
  • Celldex Therapeutics was a new Trexquant Investment position in Q2 2026.
  • Celldex Therapeutics made up 0.04% of Trexquant Investment's portfolio in Q2 2026, its #587 holding.
  • Trexquant Investment first reported a position in Celldex Therapeutics in Q4 2014 and has held it in 13 quarters since.
  • 254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.